Zeke József, Kanyó Katalin, Zeke Helga, Cseh Aron, Vásárhelyi Barna, Szilágyi András, Konc János
Infertility Center of Buda, Szt János Hospital, H-1125 Budapest, Hungary.
ScientificWorldJournal. 2011;11:1781-7. doi: 10.1100/2011/409140. Epub 2011 Oct 19.
Randomized clinical trials (RCTs) demonstrated the equal efficacy of urinary human chorionic gonadotropin (uhCG) and recombinant hCG (rhCG) products in in vitro fertilisation (IVF). However, limitations inherent with RCTs necessitate the reinforcement of RCT results in real-life. We retrospectively analyzed pregnancies after treatment with rhCG and uhCG products (n = 391, and 96, resp.). We found that laboratory-verified pregnancy occurred more frequently in rhCG patients than in those on uhCG (43% versus 30%, P = 0.02). The association remains significant (P = 0.002) after its adjustment for clinical characteristics. The prevalence of laboratory-verified pregnancies was higher with GnRH agonist use (P = 0.012) and BMI under 30 kg/m(2) (P = 0.053) while decreased the age (P = 0.014) and the number of previous failed attempts (P = 0.08). Similar (but not significant) trends were observed with rates of pregnancy filled the 24th week. These results reinforce RCTs supporting the notion that rhCG is more efficient as uhCG during IVF.
随机临床试验（RCT）证明，尿源性人绒毛膜促性腺激素（uhCG）和重组人绒毛膜促性腺激素（rhCG）产品在体外受精（IVF）中疗效相当。然而，RCT存在固有限制，因此有必要在实际应用中强化RCT结果。我们回顾性分析了使用rhCG和uhCG产品治疗后的妊娠情况（分别为n = 391例和96例）。我们发现，经实验室验证的妊娠在使用rhCG的患者中比使用uhCG的患者更常见（43%对30%，P = 0.02）。在对临床特征进行调整后，这种关联仍然显著（P = 0.002）。使用促性腺激素释放激素（GnRH）激动剂（P = 0.012）和体重指数（BMI）低于30 kg/m²（P = 0.053）时，经实验室验证的妊娠患病率较高，而年龄（P = 0.014）和既往失败尝试次数（P = 0.08）增加时患病率降低。在妊娠至第24周的发生率方面观察到类似（但不显著）的趋势。这些结果强化了RCT的结论，支持rhCG在IVF过程中比uhCG更有效的观点。
Zotero 插件